Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone

Lupus

Volumn 23, Issue 3, 2014, Pages 323-326

  Gonzalez Echavarri, C ^a   Pernas, B ^a   Ugarte, A ^a   Ruiz Irastorza, G ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

alveolar haemorrhage; glucocorticoids; hydroxychloroquine; lupus; Pancreatitis; rituximab

Indexed keywords

ALVEOLAR HAEMORRHAGE; GLUCOCORTICOIDS; HYDROXYCHLOROQUINE; LUPUS; PANCREATITIS; RITUXIMAB;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PANCREATITIS; PREDNISONE; REMISSION INDUCTION; RESPIRATORY INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84894040017     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314520842     Document Type: Article

References (14)

1. Yang Y, Ye Y, Liang L, et al. Systemic-lupus-erythematosus-related acute pancreatitis: A cohort from South China. Clin Dev Immunol. 2012 ; 2012: 568564-568564
2. Goel R, Danda D, Mathew J, et al. Pancreatitis in systemic lupus erythematosus - case series from a tertiary care center in South India. Open Rheumatol J. 2012 ; 6: 21-23
3. Al-Musawi ZS, Nabar UJ. Successful treatment of recurrent pancreatitis secondary to systemic lupus erythematosus with B-cell depletion therapy. Arch Iran Med. 2011 ; 14: 66-70
4. Santos-Ocampo AS, Mandell BF, Fessler BJ. Alveolar hemorrhage in systemic lupus erythematosus. Presentation and management. Chest. 2000 ; 118: 1083-1090
5. Zamora MR, Warner ML, Tuer R, et al. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival and outcome. Medicine (Baltimore). 1997 ; 76: 192-202
6. Martínez-Martínez MU, Abud-Mendoza C. Predictors of mortality in diffuse alveolar haemorrhage associated with systemic lupus erythematosus. Lupus. 2011 ; 20: 568-574
7. Migita K, Sasaki Y, Ishizuka N, et al. Glucocorticoid therapy and the risk of infection in patients with newly diagnosed autoimmune disease. Medicine. 2013 ; 92: 285-293
8. Buttgereit F, Straub RH, Wehling M, et al. Glucocorticoids in the treatment of rheumatic diseases: An update on the mechanisms of action. Arthritis Rheum. 2004 ; 50: 3408-3417
9. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009 ; 11: R109 - R109
10. Rojas- Serrano J, Pedroza J, Regaldo J, et al. High prevalence of infections in patients with systemic lupus erythematosus and pulmonary hemorrhage. Lupus. 2008 ; 17: 295-299
11. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology. 2012 ; 51: 1145-1153
12. Pottier V, Pierrot M, Subra JF, et al. Successful rituximab therapy in a lupus patient with diffuse alveolar haemorrhage. Lupus. 2011 ; 20: 656-659
13. Martínez-Martínez MU, Abud-Mendoza C. Recurrent diffuse alveolar haemorrhage in a patient with systemic lupus erythematosus: Long-term benefit of rituximab. Lupus. 2012 ; 21: 1124-1127
14. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010 ; 69: 20-28